| HOME >> BIOLOGY >> TECHNOLOGY |
$1,017,430 $855,415 $4,615,960 $4,196,706
Basic Earnings Per
Share(2) $0.76 $0.64 $3.44 $3.12
Average Number of Common
Shares Outstanding During
Each Period - Basic 1,338,559 1,346,087 1,342,552 1,345,386
Diluted Earnings Per
Share(2) $0.75 $0.63 $3.38 $3.08
Average Number of Common
Shares Outstanding During
Each Period - Diluted 1,367,895 1,379,180 1,374,342 1,374,053
See Notes to Results of Operations and Results of Operations -- As Adjusted.
Results of Operations -- As Adjusted
Wyeth has prepared the following presentation of its results of operations for the three months and full year ended December 31, 2007 and 2006, adjusted where noted below, to exclude productivity initiatives charges and the 2006 income tax adjustment, which are considered certain significant items during the 2007 and 2006 fourth quarter and full year.
The comparative results of operations -- as adjusted are as follows:
(In thousands except per share amounts)
(UNAUDITED) -- AS ADJUSTED
Three Months Ended Full Year Ended
12/31/2007 12/31/2006 12/31/2007 12/31/2006
Net Revenue $5,763,526 $5,220,179 $22,399,798 $20,350,655
Cost of Goods Sold(3) 1,629,443 1,448,229 6,069,333 5,458,652
Selling, General and
Administrative
Expenses(3) 1,880,580 1,772,767 6,724,921 6,423,943
Research and Development
Expenses(3) 882,437 913,224 3,256,516 3,097,712
Interest Income, Net (17,071) (6,524) (90,511) (6,646)
Other Income, Net(1) (38,795) (65,951) (290,543) (271,490)
Income Before I
'/>"/>
| SOURCE Wyeth Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |